



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	305455	Ultra Muscleze
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	FIT-BioCeuticals Limited	
<b>Postal Address</b>	Care of Blackmores Ltd PO Box 1725, Warriewood, NSW, 2102 Australia	
<b>ARTG Start Date</b>	27/06/2018	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . Ultra Muscleze

Product Type	Single Medicine Product	Effective Date	27/06/2018
--------------	-------------------------	----------------	------------

### Permitted Indications

- Maintain/support energy levels
- Relieve weariness/tiredness/fatigue/feeling of weakness
- Maintain/support body electrolyte balance
- Maintain/support bone health
- Aids/assists healthy bone development/growth/building
- Maintain/support cardiovascular system health
- Maintain/support healthy cardiovascular system function
- Decrease/reduce/relieve muscle cramps when dietary intake is inadequate
- Helps reduce occurrence of muscle cramp when dietary intake is inadequate
- Helps decrease/reduce/relieve mild muscle spasms/twitches when dietary intake is inadequate
- Maintain/support healthy muscle contraction function
- Helps enhance/promote healthy muscle function
- Maintain/support muscle function
- Maintain/support muscle relaxation
- Helps prevent dietary (state vitamin/mineral/nutrient) deficiency when dietary intake is inadequate
- Support healthy stress response in the body
- Maintain/support nerve conduction
- Maintain/support nervous system function
- Decrease/reduce feelings of aggression/irritability associated with premenstrual tension

Public Summary



**Australian Government**  
**Department of Health**  
 Therapeutic Goods Administration

Decrease/reduce/relieve mood changes/mood swings associated with premenstrual tension

Decrease/reduce/relieve breast pain/tenderness associated with premenstrual tension

Decrease/reduce/relieve symptoms of premenstrual tension

**Indication Requirements**

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.

Product presentation must not imply or refer to serious cardiovascular conditions.

Label statement: If symptoms persist, talk to your health professional.

Product presentation must not imply or refer to chronic fatigue syndrome.

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Product presentation must not imply or refer to serious musculoskeletal or neurological conditions.

**Standard Indications**

No Standard Indications included on Record

**Specific Indications**

No Specific Indications included on Record

**Warnings**

If symptoms persist consult your healthcare practitioner (or words to that effect).

This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.

Vitamins and minerals can only be of assistance if dietary intake is inadequate OR Vitamin and/or mineral supplements should not replace a balanced diet.

WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible. [Contains vitamin B6].

**Additional Product information**

**Pack Size/Poison information**

<b>Pack Size</b>	<b>Poison Schedule</b>
------------------	------------------------

**Components**

**1 . Formulation 1**

**Dosage Form** Powder, oral

**Route of Administration** Oral

**Visual Identification**

**Active Ingredients**

<b>calcium hydrogen phosphate dihydrate</b>	<b>4.938 mg/g</b>
Equivalent: calcium	1.15 mg/g
<b>calcium hydrogen phosphate dihydrate</b>	<b>.783 mg/g</b>
Equivalent: calcium	.231 mg/g
<b>calcium pantothenate</b>	<b>4.549 mg/g</b>
Equivalent: pantothenic acid	4.167 mg/g
Equivalent: calcium	382 microgram/g
<b>cyanocobalamin</b>	<b>3 microgram/g</b>
<b>d-alpha-tocopheryl acid succinate</b>	<b>11.017 mg/g</b>
<b>dibasic sodium phosphate</b>	<b>669 microgram/g</b>
Equivalent: sodium	217 microgram/g
<b>folic acid</b>	<b>25 microgram/g</b>
<b>glutamine</b>	<b>83.333 mg/g</b>
<b>heavy magnesium oxide</b>	<b>10.006 mg/g</b>
Equivalent: magnesium	6.033 mg/g
<b>levocarnitine tartrate</b>	<b>12.5 mg/g</b>

Public Summary



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

Equivalent: levocarnitine	8.525 mg/g
<b>magnesium amino acid chelate</b>	<b>353.623 mg/g</b>
Equivalent: magnesium	40.667 mg/g
<b>molybdenum trioxide</b>	<b>15 microgram/g</b>
Equivalent: molybdenum	10 microgram/g
<b>nicotinamide</b>	<b>3.333 mg/g</b>
<b>potassium aspartate</b>	<b>8.333 mg/g</b>
Equivalent: potassium	1.75 mg/g
<b>pyridoxine hydrochloride</b>	<b>8.333 mg/g</b>
Equivalent: pyridoxine	6.85 mg/g
<b>riboflavin</b>	<b>833 microgram/g</b>
<b>selenomethionine</b>	<b>10 microgram/g</b>
Equivalent: selenium	4 microgram/g
<b>taurine</b>	<b>83.333 mg/g</b>
<b>thiamine hydrochloride</b>	<b>4.167 mg/g</b>
<b>Other Ingredients (Excipients)</b>	
<b>colloidal anhydrous silica</b>	
<b>Flavour</b>	
<b>inulin</b>	
<b>malic acid</b>	
<b>Steviol glycosides</b>	

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary